Drugs / Tetradecylthioacetic acid
Tetradecylthioacetic acid
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00605787 Comparator | Jan 2002 → Jun 2003 | hyperlipidemia, type 2 diabetes mellitus | Haukeland University Hospital | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetradecylthioacetic acid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00605787 ↗ |
| Known as | 2-tetradecylthioacetic acid | “2-tetradecylthioacetic acid (TTA) is a modified fatty acid with high affinity for the PPARgamma receptor.” NCT00605787 ↗ |
| Known as | Tetradecylsulfanyl-acetic acid | ChEMBL registry synonym — accepted as the source's own label CHEMBL187734 ↗ |
| Known as | TTA | “We previously demonstrated that a modified fatty acid, tetradecylthioacetic acid (TTA), improves transport and utilization of lipids and increases mitochondrial fatty acid...” PMID 19267708 ↗ Apr 2009 |
| Action | Activate | “In cultured liver cells, TTA acted as a pan-PPAR agonist with predominant PPAR-alpha and PPAR-delta activation at low TTA concentrations.” PMID 19267708 ↗ Apr 2009 |
| Modality | Small molecule | “2-tetradecylthioacetic acid (TTA) is a modified fatty acid with high affinity for the PPARgamma receptor.” NCT00605787 ↗ |
| Route | Oral | “1000mg capsules once daily for 28 days” NCT00605787 ↗ |